Friday, November 13, 2026

KLA Projects Mid-to-High Teens Growth in Advanced Packaging as AI Chips Drive Equipment Demand

KLA Corp. forecasts mid-to-high teens growth in advanced packaging equipment for calendar 2026, outpacing broader semiconductor industry growth. The packaging equipment maker expanded indium phosphide capacity by over 20% in Q4 alone as AI chip manufacturers race to improve interconnect density. Advanced packaging is emerging as a competitive moat for chipmakers unable to access leading-edge process nodes.

KLA Projects Mid-to-High Teens Growth in Advanced Packaging as AI Chips Drive Equipment Demand
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

KLA Corp. expects its advanced packaging equipment business to grow in the mid-to-high teens percentage range through calendar 2026, CEO Michael E. Hurlston told investors. The projection signals strong demand as AI chip manufacturers prioritize packaging innovation over traditional node shrinks.

KLA increased indium phosphide capacity by more than 20% in the December quarter alone. Indium phosphide enables high-speed optical interconnects critical for AI data center infrastructure. Most initial 1.6-terabit transceivers use electro-absorption modulated lasers, and 200-gigabit lane speeds are exceeding expectations, Hurlston said.

Advanced packaging allows chipmakers to stack memory closer to processors and connect multiple dies in a single package. This approach delivers performance gains without requiring access to TSMC's most advanced manufacturing nodes, which remain supply-constrained and expensive.

The strategic shift creates opportunities for equipment makers specializing in packaging technologies. KLA's stock has outperformed the broader semiconductor equipment index as investors recognize packaging as a bottleneck. Companies unable to secure leading-edge foundry capacity are investing heavily in packaging to maintain competitive AI chip performance.

The trend extends beyond AI accelerators. High-bandwidth memory packaging, chiplet integration, and 3D stacking require specialized metrology and inspection equipment. KLA's packaging revenues are growing faster than its core semiconductor process control business, which remains cyclically exposed to memory chip demand.

For AI chip designers, packaging expertise is becoming a differentiator. Companies that optimize chip-to-chip interconnects can achieve better power efficiency and lower latency than competitors relying solely on process technology. This dynamic supports sustained equipment demand even if overall semiconductor capital expenditure moderates.

The advanced packaging market is projected to grow as percentage of total semiconductor equipment spending through 2026. Equipment makers with packaging portfolios—including KLA, ASML's assembly systems division, and Lam Research—are positioned to capture outsized share of industry investment as AI infrastructure buildout continues.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com